# An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects

> **NCT05277987** · EARLY_PHASE1 · UNKNOWN · sponsor: **Shenzhen Fifth People's Hospital** · enrollment: 18 (estimated)

## Conditions studied

- CAR T-Cell Therapy

## Interventions

- **DRUG:** HEC-016(0.5×10^6 CAR-T Cells)
- **DRUG:** HEC-016(0.5×10^6.5 CAR-T Cells)
- **DRUG:** HEC-016(0.5×10^7 CAR-T Cells)

## Key facts

- **NCT ID:** NCT05277987
- **Lead sponsor:** Shenzhen Fifth People's Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03
- **Primary completion:** 2025-03
- **Final completion:** 2025-03
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2022-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05277987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05277987, "An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05277987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*